People: Illumina Inc (ILMN.O)

ILMN.O on Nasdaq

184.82USD
22 Oct 2014
Price Change (% chg)

$5.27 (+2.94%)
Prev Close
$179.55
Open
$180.80
Day's High
$188.98
Day's Low
$178.11
Volume
2,688,171
Avg. Vol
1,181,697
52-wk High
$188.98
52-wk Low
$86.40

Search Stocks

Summary

Name Age Since Current Position

William Rastetter

65 2005 Independent Chairman of the Board

Francis deSouza

43 2014 President, Director

Jay Flatley

61 2013 Chief Executive Officer, Director

Marc Stapley

44 2012 Chief Financial Officer, Senior Vice President

David Walt

61 1998 Chairman - Scientific Advisory Board, Independent Director

Mostafa Ronaghi

45 2008 Chief Technology Officer, Senior Vice President

Christian Henry

46 2014 Senior Vice President, Chief Compliance Officer

Charles Dadswell

55 2013 Senior Vice President, General Counsel, Secretary

Nicholas Naclerio

41 2014 Senior Vice President, Corporate Development & General Manager - Enterprise Informatics

Tina Nova

60 2014 Senior Vice President, General Manager - Oncology

Tristan Orpin

47 2014 Senior Vice President & General Manager, Reproductive and Genetic Health

Matthew Posard

47 2014 Senior Vice President and General Manager, New and Emerging Market Opportunities

Paul Bianchi

52 2012 Senior Vice President - Human Resources

Richard Klausner

62 2014 Senior Vice President, Chief Medical Officer

Jeffrey Huber

46 2014 Director

Arthur Bowman

67 2007 Independent Director

Daniel Bradbury

2004 Independent Director

Karin Eastham

64 2004 Independent Director

Robert Epstein

58 2012 Independent Director

Gerald Moller

70 2010 Independent Director

Roy Whitfield

60 2007 Independent Director

Rebecca Chambers

Senior Director - Investor Relations

Biographies

Name Description

William Rastetter

Dr. William H. Rastetter, Ph.D., is Independent Chairman of the Board of Illumina, Inc., since January 2005. Dr. Rastetter is a co-founder of Receptos, Inc., a privately-held drug discovery and development company, and has been serving as Chairman of the Board since 2009. Dr. Rastetter serves as Chairman of Neurocrine Biosciences, Inc., a NASDAQ-listed biopharmaceutical company focused on neurological and endocrine diseases and disorders, a director of Regulus Therapeutics, Inc., a NASDAQ-listed biopharmaceutical company, and Chairman of Fate Therapeutics, a privately-held company focused on developing stem cell therapeutics. Dr. Rastetter served as a partner of Venrock Associates, a venture capital company from 2006 until February 2013. From 2007 to 2009, Dr. Rastetter was Chief Executive Officer and the Executive Chairman of Apoptos, Inc., a privately-held oncology research and development company, which was acquired by Receptos in 2009. At the end of 2005, Dr. Rastetter retired as the Executive Chairman of Biogen Idec Inc., a biopharmaceutical company. He had served in this position since the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. He served as Chief Executive Officer of IDEC Pharmaceuticals, a biotechnology company, from 1986 to 2003 and as Chairman of its Board of Directors from 1996 to 2003. Additionally, he served as President of IDEC Pharmaceuticals from 1986 to 2002, and as Chief Financial Officer from 1988 to 1993. From 1982 to 1986, Dr. Rastetter served in various positions at Genentech, Inc., a biotechnology company, and previously he was an associate professor at the Massachusetts Institute of Technology. Dr. Rastetter holds an S.B. in Chemistry from the Massachusetts Institute of Technology and received his M.A. and Ph.D. in Chemistry from Harvard University.

Francis deSouza

Mr. Francis A. deSouza has been appointed as President, Director of Illumina, Inc. Mr. deSouza has served as President since December 2013 and as a Director since January 2014. Prior to joining Illumina, Mr. deSouza was President, Products and Services, of Symantec Corporation, a NASDAQ-listed software technology company, from 2011 to 2013, and Mr. deSouza served as Symantec’s Senior Vice President, Enterprise Security Group, from 2009 to 2011. Prior to joining Symantec, from 2001 to 2006, he was Founder and Chief Executive Officer of IMlogic, Inc., an enterprise instant messaging software company that was acquired by Symantec in 2006, and Mr. deSouza served as Product Unit Manager, Real-time Collaboration Group, at Microsoft Corporation from 1998 to 2001. Prior to joining Microsoft, from 1997 to 1998, Mr. deSouza was co-founder and Chief Executive Officer of Flash Communications, an enterprise instant messaging company that was acquired by Microsoft in 1998. Mr. deSouza is Chairman of the board of directors of MedHelp International, a privately-held online health community. Mr. deSouza received a bachelor’s degree in electrical engineering and computer science with a minor in economics and a master’s degree from Massachusetts Institute of Technology.

Jay Flatley

Mr. Jay T. Flatley is Chief Executive Officer, Director of Illumina, Inc., since October 1999. Prior to joining Illumina, Mr. Flatley was co-founder, President, Chief Executive Officer, and a director of Molecular Dynamics, Inc., a NASDAQ-listed life sciences company focused on genetic discovery and analysis, from 1994 until its sale to Amersham Pharmacia Biotech Inc. in 1998. He served in various other positions of increasing responsibility with Molecular Dynamics from 1987 to 1994. From 1985 to 1987, Mr. Flatley was Vice President of Engineering and Vice President of Strategic Planning at Plexus Computers, a UNIX computer company. Mr. Flatley also serves as a director of Coherent, Inc., a NASDAQ-listed provider of photonics-based solutions to commercial and scientific research markets. Mr. Flatley holds a B.A. in Economics from Claremont McKenna College and a B.S. and M.S. in Industrial Engineering from Stanford University.

Marc Stapley

Mr. Marc A. Stapley has been appointed Chief Financial Officer, Senior Vice President of Illumina, Inc., effective January 20, 2012. Mr. Stapley joins Illumina from Pfizer where he served as Senior Vice President responsible for global financial processes and systems, integration efforts in both the Wyeth and King Pharmaceutical acquisitions and providing oversight to the company’s technology investment program. Prior to Pfizer, he served in a variety of senior finance roles at Alcatel-Lucent, including Americas CFO. He also worked as Finance Director and Controller for several groups at Cadence Design Systems. Stapley began his career as an Auditor at Coopers & Lybrand. Mr. Stapley holds a First Class BSc (Honors) in Mathematics from The University of Reading (England) and is a member of the Institute of Chartered Accountants in England and Wales.

David Walt

Dr. David R. Walt, Ph.D., is Chairman - Scientific Advisory Board, Independent Director of Illumina, Inc., since June 1998. Dr. Walt has been the Robinson Professor of Chemistry at Tufts University since 1995 and has been a Howard Hughes Medical Institute Professor since 2006. Dr. Walt is a Member of the National Academy of Engineering, a Fellow of the American Institute of Medical and Biological Engineers, and a Fellow of the American Association for the Advancement of Science. Dr. Walt has published over 250 papers and is named as an inventor or co-inventor of over 60 patents, many of which are directed to micro-array products. He also serves as a board member for Quanterix, Inc., a privately-held company focused on single molecule analysis for clinical diagnostics, and AuraSense, LLC, a privately-held company focused on developing therapeutic agents based on spherical nucleic acids. Dr. Walt holds a B.S. in Chemistry from the University of Michigan and received his Ph.D. in Chemical Biology from SUNY at Stony Brook.

Mostafa Ronaghi

Dr. Mostafa Ronaghi, Ph.D., is Chief Technology Officer, Senior Vice President of Illumina, Inc. Dr. Ronaghi joined Illumina in August 2008; 2002 – 2008: principal investigator at Stanford University, where Dr. Ronaghi focused on the development of novel tools for molecular diagnostic applications; 2007 – 2008: chairman and chief scientific officer for Avantome, Inc., a privately-held sequencing company co-founded by Dr. Ronaghi and acquired by Illumina in 2008.

Christian Henry

Mr. Christian O. Henry is Senior Vice President, Chief Compliance Officer of Illumina, Inc. He was Senior Vice President, General Manager - Genetic Analysis of Illumina Inc. He resigned as Chief Financial Officer effective January 4, 2012. He served as Senior Vice President, Corporate Development & Chief Financial Officer from 2009 to 2010; Senior Vice President and Chief Financial Officer from 2006 to 2009; 2006 – 2009: Senior Vice President and Chief Financial Officer;2005 – 2006: Vice President and Chief Financial Officer;2003 – 2005: chief financial officer for Tickets.com, a publicly traded, online ticket provider that was acquired by Major League Baseball Advanced Media, LP; Joined Illumina 2005.

Charles Dadswell

Mr. Charles E. Dadswell has been appointed as Senior Vice President, General Counsel, Secretary of Illumina, Inc., effective April 22, 2013. Dadswell joins Illumina with more than 20 years of leadership and legal experience at health care-focused technology companies. Most recently, he was Vice President, General Counsel for North and Latin America and Corporate Director of Global Intellectual Property at bioMerieux. In this role, he was responsible for global intellectual property matters and legal matters in North and Latin America. Prior to bioMerieux, he was General Counsel of BioDelivery Sciences International, a specialty pharmaceutical company; and oversaw US intellectual property in a variety of positions with Glaxo, GlaxoWellcome and GlaxoSmithKline. Dadswell holds a LLM in patent law and trade regulation from The George Washington University Law School, a JD from the Thomas M. Cooley Law School and a bachelor's in science from Ferris State University.

Nicholas Naclerio

Dr. Nicholas J. Naclerio, Ph.D., is Senior Vice President, Corporate Development & General Manager - Enterprise Informatics of Illumina, Inc. He was Senior Vice President - Corporate and Venture Development of the company. He was executive chairman of True Materials, a privately-held life science company that was acquired by Affymetrix, Inc. from 2007 – 2008; chief executive officer of ParAllele BioScience, Inc., a privately-held life science company that was acquired by Affymetrix, Inc. from 2003 – 2005. Mr. Naclerio became a named executive officer in fiscal 2011. He joined Illumina 2010.

Tina Nova

Dr. Tina S. Nova, Ph.D. is Senior Vice President, General Manager - Oncology of the Company. Previously, Nova co-founded the molecular diagnostics company Genoptix and served as its President and Chief Executive Officer from 2000. She was a member of the Genoptix board of directors until Novartis AG acquired the company in 2011. Nova also co-founded Nanogen Inc., a provider of molecular diagnostic tests, where she was Chief Operating Officer and President from 1994 to 2000. Prior to Nanogen, Nova was Chief Operating Officer of Selective Genetics, a biotechnology company, and also held research and management positions with Ligand Pharmaceuticals and Hybritech, a former subsidiary of Eli Lilly & Company. She holds a B.S. degree in Biological Sciences from the University of California, Irvine and a Ph.D. in Biochemistry from the University of California, Riverside.

Tristan Orpin

Mr. Tristan B. Orpin is Senior Vice President & General Manager, Reproductive and Genetic Health of Illumina, Inc. He was Senior Vice President, Commercial Operations from 2007 – 2010; Vice President of Worldwide Sales from 2002 – 2007. He joined Illumina 2002.

Matthew Posard

Mr. Matthew L. Posard is Senior Vice President and General Manager, New and Emerging Market Opportunities of Illumina, Inc. He was Senior Vice President, General Manager - Translational and Consumer Genomics of the company. He was Vice President, Global Sales from 2007 – 2012; Vice President, Marketing from 2006 – 2007. He joined Illumina 2006.

Paul Bianchi

Mr. Paul L. Bianchi is Senior Vice President - Human Resources of Illumina, Inc., since September 5, 2012. From 2009 to 2012 he served as senior vice president, human resources at Risk Management Solutions, Inc. 2005 – 2009: principal at Strayer Consulting Group, Inc.

Richard Klausner

Dr. Richard D. Klausner, M.D. is Senior Vice President, Chief Medical Officer of Illumina, Inc. Prior to joining Illumina, Dr. Klausner was managing partner of the venture capital firm, The Column Group. Previously, he held roles as Executive Director for Global Health at the Bill and Melinda Gates Foundation and as the eleventh director of the National Cancer Institute between 1995 and 2001. He has served as chief of the cell biology and metabolism branch of the National Institute of Child Health and Human Development, as well as a past president of the American Society of Clinical Investigation. He also has been Chairman of the National Science Education Standards Projects of the National Academy of Sciences. Dr. Klausner is well known for his work in cell and molecular biology, and is the author of more than 300 scientific articles and several books, in addition to receiving numerous awards and honors. He has served as an Advisor to the Presidents of the Academies for counter-terrorism, as a Liaison to the White House Office of Science & Technology Policy, and as a Chief Strategy Advisor for USAID. He currently chairs the International Advisory Board for Samsung, is the Chairman of Audax Health, and previously chaired the Strategic Oversight Council of Sanofi. He is a member of the National Academy of Sciences, the Institute of Medicine, and the American Academy of Arts and Sciences. Dr. Klausner holds an M.D. from Duke Medical School.

Jeffrey Huber

Mr. Jeffrey T. Huber is Director of the Company. Mr. Huber is Senior Vice President at Google Inc. where he works at Google[x]. Mr. Huber joined Google in 2003 and led development for Google Maps (2011-2013), Google Apps (2005-2010), and Google Ads (2003-2011). Prior to Google, Mr. Huber was Vice President of Architecture and Systems Development at eBay Inc., where he implemented eBay's massively scalable technology foundation, and Senior Vice President of Engineering at Excite@Home, where he led consumer product and infrastructure development. Mr. Huber is also a member of the board of directors and audit committee of Electronic Arts Inc.

Arthur Bowman

Mr. Arthur Blaine Bowman is an Independent Director of Illumina, Inc., since January 2007. Mr. Bowman was formerly the Chairman, President, and Chief Executive Officer of Dionex Corporation, a NASDAQ-listed manufacturer of analytical instruments. Mr. Bowman retired as President and Chief Executive Officer of Dionex in 2002 and as Chairman of the Board in 2005, and he remained a director of Dionex until its sale to Thermo Fisher Scientific Inc. in 2011. He joined Dionex in 1977 and was named President and Chief Executive Officer in 1980. Before joining Dionex, Mr. Bowman was a management consultant with McKinsey & Company, a management consulting firm, and a product engineer with Motorola Semiconductor Products Division, a communication equipment company. Mr. Bowman also serves as a director of Altera Corporation, a NASDAQ-listed provider of programmable logic solutions, and ProteinSimple, a privately-held life sciences company focused on protein research through the use of nanoproteomics. He also served as a past director of Molecular Devices Corporation, a NASDAQ-listed supplier of instruments and consumables for life science researchers, from 1985 until its sale to MDS Inc. in 2007, and of Solexa, Inc. from 2006 until its sale to Illumina in 2007. Mr. Bowman received his B.S. in Physics from Brigham Young University and an M.B.A. from Stanford University.

Daniel Bradbury

Mr. Daniel M. Bradbury is Independent Director of Illumina Inc., since January 2004. Mr. Bradbury served as Chief Executive Officer of Amylin Pharmaceuticals, Inc., a NASDAQ-listed biopharmaceutical company, from 2007 until its acquisition by Bristol-Myers-Squibb Company in 2012. From 2006 until 2012, he was a member of Amylin’s board of directors and served on its Finance and Risk Management Committee. Mr. Bradbury also served as Amylin’s President (2006-2007), Chief Operating Officer (2003-2006), and Executive Vice President (2000-2003). He joined Amylin in 1994 and also held officer-level positions in Corporate Development and Marketing. From 1984 to 1994, Mr. Bradbury held a number of sales and marketing positions at SmithKline Beecham Pharmaceuticals, a global pharmaceutical manufacturer. Mr. Bradbury serves as a director of Corcept Therapeutics Incorporated, a NASDAQ-listed biopharmaceutical company, Geron Corporation, a NASDAQ-listed biopharmaceutical company, BioMed Realty Trust, Inc., a NYSE-listed real estate investment trust, and Castle Biosciences Inc., a privately-held molecular diagnostics company. Mr. Bradbury also serves on the BioMed Ventures Advisory Committee, the Investor Growth Capital Advisory Committee, the Keck Graduate Institute’s Board of Trustees, the UCSD Rady School of Management’s Advisory Council, the University of Miami’s Innovation Corporate Advisory Council, and the University of Miami’s Diabetes Research Institute Corporate Advisory Council. He received a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education.

Karin Eastham

Ms. Karin Eastham, CPA, is an Independent Director of Illumina, Inc., since July 2004. Ms. Eastham serves on the boards of directors for several life science companies. From May 2004 to September 2008, she served as Executive Vice President and Chief Operating Officer, and as a member of the Board of Trustees, of Burnham Institute for Medical Research, a non-profit corporation engaged in basic biomedical research. From 1999 to 2004, Ms. Eastham served as Senior Vice President, Finance, Chief Financial Officer and Secretary of Diversa Corporation, a biotechnology company. She previously held similar positions with CombiChem, Inc., a computational chemistry company, and Cytel Corporation, a biopharmaceutical company. Ms. Eastham also held several positions, including Vice President, Finance, at Boehringer Mannheim Corporation, a biopharmaceutical company, from 1976 to 1988. Ms. Eastham also serves as a director for MorphoSys AG, a Frankfurt Stock Exchange-listed biotechnology company; Geron Corporation, a NASDAQ-listed biopharmaceutical company; Trius Therapeutics, Inc., a NASDAQ-listed biopharmaceutical company; and Veracyte, Inc., a privately-held molecular diagnostics company. Ms. Eastham also served as a past director of Amylin Pharmaceuticals, Inc., a NASDAQ-listed biopharmaceutical company, from 2005 until its sale to Bristol-Myers-Squibb Company in 2012; Genoptix, Inc., a NASDAQ-listed provider of specialized diagnostic laboratory services, from 2008 until its sale to Novartis AG in 2011; Tercica, Inc., a NASDAQ-listed biopharmaceutical company, from 2003 until its sale to Beaufour Ipsen Pharma in 2008; and SGX Pharmaceuticals, Inc., a NASDAQ-listed biopharmaceutical company, from 2005 until its sale to Eli Lilly and Company in 2008. Ms. Eastham received a B.S. and an M.B.A. from Indiana University and is a Certified Public Accountant.

Robert Epstein

Dr. Robert S. Epstein, M.D., has been appointed as Independent Director of Illumina, Inc., effective November 29, 2012. Dr. Epstein is an epidemiologist who worked in public health and academia before joining the private sector. Prior to this role, Dr. Epstein was Medco’s Chief Medical Officer for 13 years, where he led formulary development, clinical guideline development, drug information services, personalized medicine program development, and client analytics and reporting. Dr. Epstein is also the former President of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR), and has served on the board of directors of the Drug Information Association (DIA) and the International Society of Quality of Life. Dr. Epstein serves as a director of AVEO Pharmaceuticals, Inc., a NASDAQ-listed cancer therapeutics company, and Proteus Digital Health, a privately-held healthcare technology company. Dr. Epstein has published more than 75 peer-reviewed medical articles and book chapters and serves as a reviewer for several influential medical journals, including the New England Journal of Medicine and JAMA (The Journal of the American Medical Association). Dr. Epstein received his medical degree and B.S. in Biomedical Science from the University of Michigan and an M.S. in preventative medicine from the University of Maryland.

Gerald Moller

Dr. Gerald Moller, Ph.D., is an Independent Director of Illumina, Inc., since July 2010. Dr. Möller is currently an advisor at HBM Bio Ventures AG, a Swiss investment firm focusing on biotechnology, emerging pharmaceutical, medical technology, and related industries. Previously, Dr. Möller spent 23 years at Boehringer Mannheim in Germany, Japan, and the United States, where he held a number of leadership positions, including president of Decentralized Diagnostics, president of Advanced Diagnostics and Biochemicals, and chief executive officer of Boehringer Mannheim Therapeutics. In 1995 he became chief executive officer of the worldwide Boehringer Mannheim Group. Following Boehringer’s acquisition by Roche in 1998, Dr. Möller became head of Global Development and Strategic Marketing, Pharmaceuticals, and a member of the Executive Committee at Hoffmann LaRoche where he served until the end of 1998. In addition to Illumina, Dr. Möller sits on several life sciences and diagnostics boards, including Morphosys AG, a Frankfurt Stock Exchange-listed biotechnology company; Bionostics, Inc., a privately-held developer and manufacturer of calibrators and quality control products for diabetes diagnostics test systems; Invendo-Medical GmbH, a privately-held medical technology company; Adrenomed AG, a privately-held biopharmaceutical company; and Definiens AG, a privately-held provider of image analysis for digital pathology. Dr. Möller served as a past director of Vivacta Limited, a privately-held medical diagnostics company, until its sale to Novartis AG in December 2012. Dr. Möller also is vice-chairman of the Foundation for Innovative New Diagnostics (FIND), a product development and implementation partnership financed in part by the Bill & Melinda Gates Foundation. He holds a Ph.D. in physical chemistry from the University of Kiel in Germany.

Roy Whitfield

Mr. Roy A. Whitfield is an Independent Director of Illumina, Inc., since January 2007. Mr. Whitfield is the former Chairman of the Board and Chief Executive Officer of Incyte Corporation (formerly Incyte Genomics), a NASDAQ-listed drug discovery and development company he co-founded in 1991. From 1993 to 2001, Mr. Whitfield served as its Chief Executive Officer and, from November 2001 until his retirement in June 2003, as its Chairman. Mr. Whitfield remains on the board of Incyte Corporation. From 1984 to 1989, Mr. Whitfield held senior operating and business development positions with Technicon Instruments Corporation, a medical instrumentation company, and its predecessor company, Cooper Biomedical, Inc., a biotechnology and medical diagnostics company. Earlier, Mr. Whitfield spent seven years with the Boston Consulting Group’s international consulting practice. In addition to serving on the Incyte Board, since 2000 he has served as a director of Nektar Therapeutics, a NASDAQ-listed clinical-stage biopharmaceutical company, and he also serves as a director of Station X Inc., a privately-held developer of software products for analyzing largescale human genome information. Mr. Whitfield also served as a past director of Solexa, Inc. from 2006 until its sale to Illumina in 2007. Mr. Whitfield received a B.S. in Mathematics from Oxford University and an M.B.A. from Stanford University.

Rebecca Chambers

Basic Compensation

Search Stocks